Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan Takeda Pharmaceutical has exercised its option to acquire PvP Biologics in a deal valued at around $330m.
The head office of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan (Credit: GFDL, Cc-by-sa-2.5)
Subscribe to our email newsletter
PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is being developed to treat uncontrolled celiac disease.
The TAK-062 is a potent super glutenase protein, which degrades ingested gluten. It was computationally designed for the treatment of celiac disease, a serious autoimmune disease.
PvP Biologics president and CEO Adam Simpson said: “TAK-062 was engineered in 2015 to address the challenges seen by previous glutenases in development for the treatment of celiac disease – their lack of specificity for gluten and activity in the acidic conditions of the stomach.”
The Japanese firm exercised its option to purchase PvP Biologics for a pre-negotiated upfront payment and development and regulatory milestones of up to $330m.
Earlier, both firms signed a development and option agreement to enable PvP Biologics to conduct research and development via Phase 1 proof-of-mechanism study of TAK-062 in exchange for funding by Takeda related to a pre-defined development plan.
The TAK-062, which enzymatically digests gluten, has shown enhanced catalytic activity compared to other glutenases.
It will degrade the immune-reactive parts of gluten before they exit the stomach, helping to avoid the immune response to gluten and eliminate the symptoms and intestinal damage caused by celiac disease
The Phase 1 study evaluated the safety and tolerability of TAK-062 in both healthy volunteers and people with celiac disease. Its capacity to degrade ingested gluten was assessed in healthy volunteers.
Takeda aims to start a Phase 2b efficacy and dose-ranging study of TAK-062 in patients with the uncontrolled disease who maintain a gluten-free diet.
Takeda therapeutic area unit gastroenterology head Dr Asit Parikh said: “Many people living with celiac disease manage their symptoms by following a gluten-free diet, but there is no treatment for those who continue to experience severe symptoms.
“PvP Biologics’ work demonstrated that TAK-062 is a highly targeted therapy that could change the standard of care in celiac disease.”
In November 2019, Takeda Pharmaceutical opened a new dengue vaccine manufacturing facility in Singen, Germany.
